VINC
Price:
$0.73
Market Cap:
$22.54M
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.[Read more]
Industry
Biotechnology
IPO Date
2020-05-27
Stock Exchange
NASDAQ
Ticker
VINC
According to Vincerx Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.64. This represents a change of -69.43% compared to the average of -2.09 of the last 4 quarters.
The mean historical PE Ratio of Vincerx Pharma, Inc. over the last ten years is -223.82. The current -0.64 PE Ratio has changed -71.41% with respect to the historical average. Over the past ten years (40 quarters), VINC's PE Ratio was at its highest in in the June 2022 quarter at -0.40. The PE Ratio was at its lowest in in the March 2020 quarter at -2966.29.
Average
-223.82
Median
-11.21
Minimum
-1079.61
Maximum
-0.38
Discovering the peaks and valleys of Vincerx Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 66.75%
Maximum Annual PE Ratio = -0.38
Minimum Annual Increase = -97.48%
Minimum Annual PE Ratio = -1079.61
Year | PE Ratio | Change |
---|---|---|
2023 | -0.63 | 66.75% |
2022 | -0.38 | -96.65% |
2021 | -11.21 | -58.85% |
2020 | -27.25 | -97.48% |
The current PE Ratio of Vincerx Pharma, Inc. (VINC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.07
5-year avg
-223.82
10-year avg
-223.82
Vincerx Pharma, Inc.’s PE Ratio is less than Spero Therapeutics, Inc. (4.02), less than Bolt Biotherapeutics, Inc. (-0.37), greater than Coherus BioSciences, Inc. (-4.07), greater than Gracell Biotechnologies Inc. (-12.15), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Applied Therapeutics, Inc. (-6.88), less than Lyra Therapeutics, Inc. (-0.15), greater than Shattuck Labs, Inc. (-0.73), greater than BioAtla, Inc. (-1.01), greater than Monopar Therapeutics Inc. (-2.27), less than Senti Biosciences, Inc. (-0.18), less than Processa Pharmaceuticals, Inc. (-0.35), greater than Fresh Tracks Therapeutics, Inc. (-3.04), greater than LAVA Therapeutics N.V. (-1.90), less than TRACON Pharmaceuticals, Inc. (0.08), greater than Rezolute, Inc. (-3.66), greater than XOMA Corporation (-17.65), greater than Sio Gene Therapies Inc. (-4.77), greater than Protara Therapeutics, Inc. (-0.93), less than Vaccinex, Inc. (-0.26), greater than Miromatrix Medical Inc. (-3.41), greater than Surrozen, Inc. (-0.67),
Company | PE Ratio | Market cap |
---|---|---|
4.02 | $70.26M | |
-0.37 | $24.68M | |
-4.07 | $119.82M | |
-12.15 | $989.87M | |
-0.98 | $8.20M | |
-6.88 | $884.31M | |
-0.15 | $15.54M | |
-0.73 | $58.23M | |
-1.01 | $106.34M | |
-2.27 | $16.23M | |
-0.18 | $10.26M | |
-0.35 | $3.88M | |
-3.04 | $4.36M | |
-1.90 | $44.96M | |
0.08 | $452.97K | |
-3.66 | $272.97M | |
-17.65 | $323.51M | |
-4.77 | $30.70M | |
-0.93 | $36.93M | |
-0.26 | $4.41M | |
-3.41 | $92.95M | |
-0.67 | $36.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vincerx Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vincerx Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Vincerx Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Vincerx Pharma, Inc. (VINC)?
What is the highest PE Ratio for Vincerx Pharma, Inc. (VINC)?
What is the 3-year average PE Ratio for Vincerx Pharma, Inc. (VINC)?
What is the 5-year average PE Ratio for Vincerx Pharma, Inc. (VINC)?
How does the current PE Ratio for Vincerx Pharma, Inc. (VINC) compare to its historical average?